Risk of inappropriate advertising distribution
First written in FY2022. 4 of 8 entries say "Restated". Latest entry: FY2026.
23 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「The Group works to ensure the legality of its advertising content so as not to violate these laws and regulations. However, if deficiencies arise in these measures for any reason, the Group's business and results may be affected.」
The company again discloses the risk of inappropriate advertising distribution, including violations of the Act against Unjustifiable Premiums and Misleading Representations, the Pharmaceuticals and Medical Devices Act and other laws, together with measures to ensure the legality of advertising content. - FY2026-H1DroppedAnnual report
「No applicable items.」
The business and other risks section of the interim report contains no specific mention of the risk of inappropriate advertising distribution. This does not establish that the risk itself has disappeared. - FY2025RestatedAnnual report
「We work to ensure the legality of advertising content so that it does not violate these laws. However, if these measures are inadequate for any reason, this could affect our business and performance.」
The company again discloses the risk of inappropriate advertising distribution, including violations of the Act against Unjustifiable Premiums and Misleading Representations, the Pharmaceuticals and Medical Devices Act and other laws, together with measures to ensure the legality of advertising content. - FY2025-H1DroppedAnnual report
「No applicable items.」
The business and other risks section of the interim report contains no specific mention of the risk of inappropriate advertising distribution. This does not establish that the risk itself has disappeared. - FY2024RestatedAnnual report
「We work to ensure the legality of advertising content so that it does not violate these laws. However, if these measures are inadequate for any reason, this could affect our business and performance.」
The company again discloses the risk of inappropriate advertising distribution, including violations of the Act against Unjustifiable Premiums and Misleading Representations, the Pharmaceuticals and Medical Devices Act and other laws, together with measures to ensure the legality of advertising content. - FY2024-Q1DroppedAnnual report
「No applicable items.」
The business and other risks section of the quarterly report states, “There are no applicable matters,” and contains no specific mention of the risk of inappropriate advertising distribution. - FY2023RestatedAnnual report
「We work to ensure the legality of advertising content so that it does not violate these laws. However, if these measures are inadequate for any reason, this could affect our business and performance.」
The company continues to describe the risk of inappropriate advertising distribution and measures to ensure the legality of advertising content. - FY2022First statedAnnual report
「However, if these measures are inadequate for any reason, this could affect our business and performance.」
While managing the quality of advertising content to ensure that it does not violate the Act against Unjustifiable Premiums and Misleading Representations, the Pharmaceuticals and Medical Devices Act or other laws, the company identifies the impact of inadequate measures as a risk.